Clinical Studies

No. Diagnosis Title Author(s) Year Medication(s) Design Major Outcome(s)
21 Inflammation Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Ben-Horin S,
Lahat A,
Lang A
2011 Cannabis Open Study Significant improvement of several symptoms.
22 Diarrhoea,
Gastrointestinal disorder
Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients with Non-Constipated Irritable Bowel Syndrome. Burton D,
Busciglio I,
Camilleri M,
Carlson P,
Szarka LA,
Wong BS,
Zinsmeister AR
2011 Delta-9-THC Controlled Study Dronabinol reduces fasting motility of the colon in IBS patients with diarrhoea
23 Pain An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Huggins JP,
Langman S,
Smart TS,
Taylor L,
Young T.
2012 Other cannabinoids Controlled Study A FAAH inhibitor was not more effective than a placebo.
24 Posttraumatic stress disorder Medical cannabis use in post-traumatic stress disorder: a naturalistic observational study. Reznik I. 2011 Cannabis Open Study In most cases a significant improvement in quality of life and pain, with some positive changes in severity of posttraumatic stress disorder was observed.
25 Gastrointestinal disorder,
Cannabis use amongst patients with inflammatory bowel disease. Gordon A,
Lal S,
Prasad N,
Ryan M,
Silverberg MS,
Steinhart H,
Tangri S
2011 Cannabis Survey Cannabis use is frequent in patients with chronic intestinal inflammation
26 Pain Palmitoylethanolamide in the Treatment of Chronic Pain Caused by Different Etiopathogenesis. Di Paolo A,
Gatti A,
Gianfelice V,
Lazzari M,
Sabato AF.,
Sabato E
2012 Other cannabinoids Open Study Significant pain relief with palmitoylethanolamide (PEA)
27 Multiple sclerosis,
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Ambler Z,
Cefaro L,
Comi G,
Davies P; the Sativex Spasticity Study Group,
Erdmann A,
Gasperini C,
Klimek A,
Mares J,
Montalban X,
Novakova I,
Novotna A,
Pozzilli C,
Ratcliffe S,
Rossi P,
Stelmasiak Z,
Vachova M,
Zapletalova O
2011 Cannabis Controlled Study The cannabis extract significantly reduced spasticity.
28 - Cannabinoid effects on ventilation and breathlessness: A pilot study of efficacy and safety. Cummin AR,
Guz A,
Holdcroft A,
Moosavi S,
Murphy K,
Nazir MS,
Pickering EE,
Semple SJ,
Snow TM
2011 Cannabis Controlled Study With cannabis participants felt less breathless
29 Multiple sclerosis,
Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. Bentley H,
Corey-Bloom J,
Gamst A,
Gouaux B,
Jin S,
Marcotte TD,
Wolfson T
2012 Cannabis Controlled Study Smoked cannabis was superior to placebo in reducing spasticity and pain.
30 - The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Boeckxstaens GE,
Klooker TK,
Leliefeld KE,
Van Den Wijngaard RM
2011 Delta-9-THC Controlled Study THC did not modify visceral perception to rectal distension.